Maintaining Independence & Quality of Life in Aging Adults Through

Status Not yet recruiting

Clinical Trial Summary

Mild Cognitive Impairment, Alzheimer's Disease and Parkinson's Disease all represent a range of degenerative conditions that have cognitive impairments which all limit the ability for older individuals to self-manage care, participate in daily activities and community participation. The consequences of these progressive diseases increase the requirement for residential care, associated medical costs and may negatively impact the overall quality of life and mental health for individuals. According to the Alzheimer Society of Canada, over the next few decades, more than 1 million Canadian's will be living with decreased cognitive ability and will require an increased amount of support, whether through family or institutional sources.

Currently, there are few cognitive programs for individuals diagnosed with mild cognitive impairment or for individuals wishing to maintain their current level of cognitive ability which translates to meaningful improvements in daily living and independence, as well as generalized intelligence. To date, the Watson Centre Society for Brain Health (WCSBH) has successfully improved cognitive capacity, executive function and quality of life for over 100 individuals following a wide range of brain injury, and currently has a 77% return to work rate following completion of the full program. The program includes a combination of physical exercise, cognitive training and mindfulness meditation.

The purpose of the research study is to explore the impact of an interdisciplinary cognitive rehabilitation program has upon the cognitive functioning and quality of life for individuals who are assessed to have mild cognitive impairment (MCI). In particular, the aims of this study include: 1) To evaluate changes in cognition and quality life in older adults with MCI. 2) To explore the potential for intensive cognitive intervention in slowing cognitive degeneration in older adults with MCI.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04539132
Study type	Interventional
Source	Kwantlen Polytechnic University
Contact	Tess Kroeker, PhD
Phone	7788778050
Email	Tess.Kroeker@kpu.ca
Status	Not yet recruiting
Phase	N/A
Start date	September 1, 2020
Completion date	October 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04513106` - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial	N/A
Recruiting	`NCT06011681` - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting	`NCT04522739` - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease	Phase 4
Active, not recruiting	`NCT03167840` - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment	N/A
Active, not recruiting	`NCT03676881` - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting	`NCT05041790` - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment	Phase 4
Recruiting	`NCT04121156` - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment	N/A
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Completed	`NCT02774083` - Cognitive Training Using Feuerstein Instrumental Enrichment	N/A
Completed	`NCT01315639` - New Biomarker for Alzheimer's Disease Diagnostic	N/A
Enrolling by invitation	`NCT06023446` - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed	`NCT04567745` - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers	Phase 1
Recruiting	`NCT05579236` - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed	`NCT03583879` - Using Gait Robotics to Improve Symptoms of Parkinson's Disease	N/A
Terminated	`NCT02503501` - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease	Phase 2
Not yet recruiting	`NCT03740178` - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)	Phase 1
Active, not recruiting	`NCT05204940` - Longitudinal Observational Biomarker Study
Recruiting	`NCT02663531` - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease	N/A
Recruiting	`NCT06150352` - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting	`NCT03507192` - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Maintaining Independence and Quality of Life in Aging Adults Through Targeted Cognitive Training

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms